Drug intelligence / Profile preview

aceclofenac + paracetamol (Uniark Healthcare)

Development stage
Unknown
Lead developer
Uniark Healthcare
Modality
Small Molecules
Administration
Oral
01

Overview

Fibmol-P is a fixed-dose combination analgesic and anti-inflammatory medication marketed by Uniark Healthcare. It contains aceclofenac, a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID), and paracetamol (acetaminophen), a widely used analgesic and antipyretic. Aceclofenac works by inhibiting the cyclooxygenase (COX) enzymes, particularly COX-2, to block the synthesis of inflammatory prostaglandins. Paracetamol complements this by providing additional pain relief and fever reduction, likely through central COX inhibition and modulation of serotonergic pathways. Fibmol-P is indicated for the symptomatic treatment of pain and inflammation in conditions such as osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and various musculoskeletal disorders.

Brand names
Fibmol-P
Other names
Aceclofenac and Paracetamol Tablet
02

Targets

PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on aceclofenac + paracetamol (Uniark Healthcare).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on aceclofenac + paracetamol (Uniark Healthcare).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call